SecBot SecBot

PFAS Accountability Act of 2024

H.R. 7194 Rep. Madeleine Dean (D-PA-4) In committee
  1. Introduced Feb 1
  2. Committee Feb 1
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 1, 2024Next: House vote
999d ago Feb 2, 2024: Referred to the Subcommittee on Environment, Manufacturing, and Critical Materials.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Member trades
5trades in the last 90 days
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Industrials 1
Search all 1 companies, their asks and price moves Subscribe

Summary

The PFAS Accountability Act of 2024 amends the Toxic Substances Control Act to create a federal legal claim and remedy for individuals significantly exposed to per- and polyfluoroalkyl substances (PFAS), aiming to encourage research and accountability for their irresponsible discharge.

Sec. 4, Cause of action and remedies: This section adds a new section 25 to the Toxic Substances Control Act. It defines PFAS as a substance with at least one fully fluorinated carbon atom. It creates a federal cause of action allowing an individual significantly exposed to PFAS, or with reasonable grounds to suspect such exposure, to sue in federal court for legal and equitable relief against any person who engaged in any part of a manufacturing process that created the PFAS and foresaw or should have foreseen human exposure. Courts may award medical monitoring if the individual was significantly exposed, has an increased risk of a PFAS-associated disease, has a reasonable basis for periodic diagnostic exams different from usual, and those exams are effective. A presumption of significant exposure can be established by showing the defendant created the PFAS and released it where the individual was exposed for at least one year, or by offering test results showing PFAS in the individual's body. In class actions, this presumption is established for the class by similar evidence for a representative portion. A defendant can rebut the presumption for individuals without test results by providing independent testing at their own cost. If toxicological data is insufficient to determine increased risk, a court may lower the scientific proof standard and order new studies. This section does not preempt state law claims or remedies.

Summary of the bill text as introduced in House (Feb 1, 2024), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.